Fig. 2.

Efficacy of CAR-T cells in an SLE mouse model. a Working scheme of CAR-T cell manufacture and adoptive transfer in a mouse experiment. The percentage of blood CD19⁺ cells at 1 week (b, c) or 9 weeks (d) after transfer was analyzed by flow cytometry; the percentage of blood CD138⁺ cells at 1 week (e) or 9 weeks (f) after transfer was analyzed by flow cytometry. Live CD45⁺ cells were gated and plotted (b–f). g Effector cells, lymphocytes isolated from TBI + CAR-T cell-treated mice 9 weeks after transfer; target cells, fresh splenocytes labeled with CellTrace Violet; the percentage of lysed B cells was analyzed by flow cytometry after 24 h of coculture. The data are representative of at least two independent experiments with similar results. The data were analyzed by Student’s t test, and significance is indicated by *P < 0.05, ****P < 0.0001, and ns no significant differences